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Activation of signal transduction by the receptor tyrosine kinase, ﬁbroblast growth factor receptor (FGFR),
results in a cascade of protein-protein interactions that rely on the occurrence of speciﬁc tyrosine
phosphorylation events. One such protein recruited to the activated receptor complex is the nonreceptor
tyrosine kinase, Src, which is involved in both initiation and termination of further signaling events. To
gain a further understanding of the tyrosine phosphorylation events that occur during FGF signaling,
with a speciﬁc focus on those that are dependent on Src family kinase (SFK) activity, we have applied
SILAC combined with chemical inhibition of SFK activity to search for phosphorylation events that are
dependent on SFK activity in FGF stimulated cells. In addition, we used a more targeted approach to
carry out high coverage phosphopeptide mapping of one Src substrate protein, the multifunctional
adaptor Dok1, and to identify SFK-dependent Dok1 binding partners. From these analyses we identify
80 SFK-dependent phosphorylation events on 40 proteins. We further identify 18 SFK-dependent Dok1
interactions and 9 SFK-dependent Dok1 phosphorylation sites, 6 of which had not previously been
known to be SFK-dependent.
Keywords: phosphorylation • phosphopeptide • phosphoproteomics • phosphotyrosine • SILAC •
quantitative mass spectrometry • FGFR • Src • Dok1
Introduction
The ﬁbroblast growth factor (FGF) family of ligands and
receptors execute a wide range of biological functions in
development, tissue repair, angiogenesis and cellular homeo-
stasis.
1-3 Dysregulation of the FGF signaling axis by a diversity
of mechanisms is a frequent feature of a range of different
tumor cell types
4,5 and, as a result, the FGF pathway is the
target for the development of small molecule kinase inhibitors
and other forms of therapeutic intervention.
2 However, to
better inform the development of therapeutic interventions in
the FGF pathway, and analyze their molecular actions, a
complete understanding of the architecture of the downstream
processes activated by FGF signaling is required. In this study
we apply a differential phosphoproteomics approach to the
identiﬁcation of phosphorylation events mediated during
activation of FGFR signaling.
Current understanding of the FGF signaling pathway holds
that, following receptor dimerization by ligand engagement,
activation of the intrinsic receptor tyrosine kinase leads to
phosphorylation of key tyrosine residues on the receptor itself
and the receptor-associated docking protein FRS2.
6,7 These
phosphorylation events provide the basis for recruitment of
effector proteins bearing sequence-speciﬁc phosphotyrosine
recognition domains, which leads to further recruitment of
downstream effectors and activation of intracellular signaling
processes. The most prominent pathways associated with this
mechanism are activation of the Ras/Raf/ERK pathway via
recruitment of the adaptor protein Grb2 and the RasGEF SOS
8,9
activation of the PI3 kinase/PDK/Akt pathway via recruitment
of the adaptor protein Gab1
10,11 and activation of phospholi-
pase C via direct recruitment, via its SH2 domain, to the
receptor.
12 Recent studies have provided further elaboration
of this core pathway. A targeted mass spectrometric analysis
of proteins that interact with activated FGFRs
13 identiﬁed a
plethora of proteins associated with intracellular vesicular
trafﬁcking. One such partner, the small GTPase Rab5, has been
shown to be crucial for sustaining propagation of the Ras/Raf/
ERK, but not the PI3K/PDK/Akt signal. Additionally the non
receptor tyrosine kinase c-Src has been shown to be rapidly
recruited to the activated receptor complex, and Src kinase
activity is required for both the initiation of FGF signaling and
termination of the Ras/Raf/ERK pathway but not the PI3K/
PDK/Akt pathway.
14 These ﬁndings point to the existence of
further, as yet uncharacterized, mediators of FGFR signaling
that are targets for Src kinase-mediated phosphorylation and
functionally implicated in FGFR trafﬁcking of activated FGFRs.
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Published on Web 03/12/2010During recent years, phosphoproteomic studies have suc-
cessfully identiﬁed large numbers of phosphorylation sites.
15-17
This success is due in large part to efﬁcient enrichment
techniques for phosphopeptides and improvements in mass
spectrometric instrumentation.
18 To obtain more biologically
informative results from these types of studies, some form of
quantitation can be applied.
19 In particular, stable isotope
labeling with amino acids in cell culture (SILAC) is capable of
quantifying even relatively subtle changes in protein levels.
20,21
Recently, software has been designed speciﬁcally to both
improve SILAC data analysis and to cope with the large data
sets generated from these experiments.
22
In this study, we set out to identify further direct and indirect
phosphorylation events on protein targets for Src family kinases
(SFKs) downstream of FGFR using ultrahigh resolution mass
spectrometry techniques.
23 Previous proteomic studies of the
FGFR tyrosine kinase pathway have relied on overexpression
of FGFR.
13,24,25 Rather than overexpress FGFR, we chose to
combine FGF stimulation with pervanadate treatment to
maximize the levels of tyrosine phosphorylated substrates. A
similar approach using pervanadate treatment has been used
in previous phosphoproteomics studies.
21,26-28 We applied
SILAC combined with chemical inhibition of SFK activity to
search for phosphorylation events that are dependent on SFK
activity in FGF stimulated cells. SILAC has previously been used
to study Src-substrates in cells overexpressing Src,
28 in Src-
transformed cells,
29 and using chemical inhibition of SFK
activity downstream of the PDGF receptor.
30 However, much
of the data obtained identiﬁes proteins as tyrosine phospho-
rylated without localizing the exact site of phosphorylation, and
information regarding regulation on speciﬁc tyrosine phos-
phorylation sites of Src substrates is lacking.
Here, we identify 80 SFK-dependent phosphorylation events
on 40 target proteins, including known Src substrates, down-
stream kinases and adaptor proteins. To illustrate further
application of SILAC techniques to characterization of speciﬁc
SFK-mediated phosphorylation events, we used a more targeted
approach to carry out high coverage phosphopeptide mapping
of one Src substrate protein, the multifunctional adaptor Dok1,
and to identify SFK-dependent Dok1 binding partners.
Collectively, these results signiﬁcantly expand the range of
proteins implicated in the FGF signaling pathway and reveal
potential new targets for therapeutic intervention in FGF and
Src signaling.
Experimental Procedures
Cell Culture. Mouse NIH 3T3s cells were cultured at 37 °C,
5% CO2 in DMEM containing 2 mM L-Glutamine (Lonza),
supplemented with 0.1 mg/mL streptomycin, 0.2 U/mL peni-
cillin (Sigma), and 10% v/v donor bovine serum (Labtech
International). Human embryonic kidney epithelial 293T cells
were cultured as above; however, donor bovine serum was
substituted for 10% v/v fetal calf serum (Labtech International).
SILAC Labeling. For SILAC labeling, NIH 3T3 cells were
cultured in amino acid deﬁcient DMEM (Thermo) supple-
mented with either 0.1 mg/mL isotopically normal L-Lysine and
L-Arginine (Sigma) or “heavy” 13C6 L-Lysine and 13C6
15N4
L-Arginine (Goss Scientiﬁc), 10% dialyzed FBS (Thermo), 2 mM
L-Glutamine, 0.1 mg/mL streptomycin, and 0.2 U/ml penicillin.
293T cells were cultured as above, with the addition of 0.5 mg/
mL proline (Sigma) in the media.
31 Cells were grown for at least
ﬁve doubling times prior to use in order for the cells to fully
incorporate the labeled amino acids.
Cloning and Transfection. The human open reading frame
for Dok1 was supplied in a Gateway (Invitrogen) pDONR vector
from Open Biosystems. The insert encoding Dok1 was cloned
into the Gateway compatible mammalian expression vector,
Myc-PRK5 (gift from Laura Machesky) using Gateway cloning.
Cells were transfected using Genejuice (Novagen) according
to manufacturers’ instructions and allowed to overexpress
transfected protein for 48 h.
Cell Treatment and Cell Lysis. Following overnight serum
starvation in media containing 0.1% serum, cells were either
pretreated with 25 µM SU6656 for 1 h, followed by addition of
2 mM sodium pervanadate for 20 min, and then 20 ng/mL
FGF2 for 30 min, or treated as above in the absence of SU6656.
Prior to lysis, cells were washed twice in cold phosphate-
buffered saline (PBS) and then lysed at 4 °C in 1 mL lysis buffer
(50 mM Tris-HCl pH 7.4, 150 mM NaCl, 1 mM EDTA, 1% Triton
X-100 (w/v), 1 mM Na3VO4, 50 mM NaF, 25 mM  -glycero-
phosphate and 1 tablet of protease inhibitor mixture (Roche
Molecular Diagnostics) per 10 mL of buffer) per 175-cm2 ﬂask
of cells. After incubation on ice for 30 min, the lysates were
centrifuged at 15 000× g at 4 °C for 20 min. Total protein
concentrations of the cleared lysates were then determined
using the Coomassie (Bradford) Protein Assay Kit (Pierce
Biotechnology Inc.), according to the manufacturers’ instructions.
Western Blotting. Whole cell lysates were run on 4-12% Bis-
Tris gels (Invitrogen). Protein was transferred to FL polyvi-
nylidene diﬂuoride membrane (Millipore Corp.) at 100 V for
1 h 15 min. To block the membranes they were washed in
methanol and allowed to dry. Primary antibodies were incu-
bated with the membrane overnight at 4 °C in Odyssey Blocking
Buffer (Licor Biosciences) containing 0.1% Tween-20. The blot
was washed three times for 15min in PBS/0.1% Tween-20 (PBS-
T) and probed with the IRDye conjugated secondary antibody
(Licor Biosciences) diluted in Odyssey Blocking Buffer/0.1%
Tween-20/0.01% SDS for1ha troom temperature, in the dark.
The membrane was washed three times in PBS-T, followed by
a ﬁnal wash in PBS (no Tween 20). Membranes were visualized
using ﬂuorescence detection on the Odyssey Infared Imaging
System (Licor Biosciences). Primary antibodies used in this
study were obtained from Santa Cruz (FRS2, ERK, ERK pY204)
and Cell Signaling Technology (FGFR1 pY653/pY654, FRS2
pY196, Src, Src pY416, AKT, and AKT pT308).
Immunoprecipitation. For the phosphotyrosine immuno-
precipitation (IP), agarose-conjugated antiphosphotyrosine
(clone 4G10) antibody (Upstate) was used. Whole cell lysates
(WCL) were initially precleared with protein A agarose beads
for 30 min at 4 °C (25 mg/100 µL beads) before mixing with
antibody-conjugated beads (25 mg WCL/100 µL beads). Fol-
lowing overnight incubation at 4 °C, beads were washed six
times in a 100-fold excess of ice-cold PBS. To address repro-
ducibility, four replicates of the SILAC phosphotyrosine IPs
were carried out. For Myc-Dok1 IPs, Myc-Dok1 antibody 9E10
(Roche) was conjugated to Protein G Dynabeads, as per
manufacturers’ instructions (Invitrogen; 10 µg Ab/25 µL Dyna-
beads), prior to addition of cell lysate. WCLs (10 mg) from the
heavy and light cell populations were immunoprecipitated
separately. WCLs were mixed at 4 °C with conjugated beads
(10 mg/170 µL conjugated beads) for 1 h and beads were
washed twice in a 20-fold excess of lysis buffer. Beads from
both “heavy” and “light” IPs were then mixed and washed a
further three times, again in a 20-fold excess of lysis buffer.
Following addition of reduced sample buffer, protein samples
were run on 4-12% Bis-Tris gels (Invitrogen) and Coomassie
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and samples from each IP were analyzed in duplicate.
Trypsin Digestion and Phosphopeptide Enrichment of
Samples. Following the phosphotyrosine IPs, the agarose-
conjugated beads were resuspended in 8 M urea, 50 mM
ammonium bicarbonate. The beads were then heated at 95 °C
for 5 min and eluted proteins were removed in the supernatant
after centrifugation. The protein mixtures were diluted to 1 M
urea, reduced (4 mM DTT) and alkylated (8 mM iodoaceta-
mide) in 50 mM ammonium bicarbonate prior to overnight
trypsin digestion (1:100 enzyme:protein; Trypsin Gold; Prome-
ga, Madison, WI).
Following the Myc-Dok1 IPs, excised bands from Coomassie-
stained gels were destained, reduced (10 mM DTT) and
alkylated (55 mM iodoacetamide) in 25 mM ammonium
bicarbonate prior to overnight in-gel trypsin digestion (12.5 ng/
µL; Trypsin Gold; Promega, Madison, WI).
Digested samples were acidiﬁed by addition of triﬂuoroacetic
acid (0.5% ﬁnal volume). Peptides from the anti-pY IPs were
desalted (Peptide concentration and desalting Macrotrap;
Michrom Bioresources, Pleasanton, CA) and dried by vacuum
centrifugation. Phosphopeptides were enriched using TiO2 as
described.
23 The resulting peptide mixtures were analyzed by
liquid chromatography tandem mass spectrometry (LC-MS/
MS).
Mass Spectrometry. Online liquid chromatography was
performed by use of a Micro AS autosampler and Surveyor MS
pump (Thermo Electron, Bremen, Germany). Peptides were
loaded onto a 75 µm (internal diameter) Integrafrit (New
Objective, Woburn, MA) C8 resolving column (length 10 cm)
and separated over a 40 min gradient from 0% to 40%
acetonitrile (Baker, Holland). Peptides eluted directly (∼300 nL/
min) via a Triversa nanospray source (Advion Biosciences,
Ithaca, NY) intoa7TL T QF Tmass spectrometer (Thermo
Fisher Scientiﬁc). The mass spectrometer alternated between
a full FT-MS scan (m/z 395-1600), subsequent CID MS/MS
scans of the ﬁve most abundant ions, and, if a neutral loss of
98 Da from the precursor ion was observed in the CID mass
spectrum, an MS3 scan of the neutral loss ion. Survey scans
were acquired in the ICR cell with a resolution of 100 000 at
m/z 400. Precursor ions were isolated and subjected to CID in
the linear ion trap. Isolation width was 3 Th. Only multiply
charged precursor ions were selected for MS/MS. CID was
performed with helium gas at a normalized collision energy of
35%. Precursor ions were activated for 30 ms. Data acquisition
was controlled by Xcalibur 2.0 software.
Identiﬁcation and Quantiﬁcation of Peptide and Proteins.
Mass spectra were processed using the MaxQuant software
(version 1.0.12.31).
22,32 Data were searched, using MASCOT
version 2.2 (Matrix Science), against a concatenated database
consisting of the mouse or human IPI database supplemented
with common contaminants (including keratins, trypsin, BSA)
and the reversed-sequence version of the same database. The
mouse database contained 111 130 protein entries (55 565 of
which were reversed-sequence versions). The human database
contained 148 380 protein entries (74 190 of which were
reversed-sequence versions). The search parameters were:
minimum peptide length 6, peptide tolerance 30 ppm, mass
tolerance 0.5 Da, cleavage enzyme trypsin/P, and a total of 2
missed cleavages were allowed. Carbamidomethyl (C) was set
as a ﬁxed modiﬁcation and oxidation (M) and acetylation
(Protein N-term) were set as variable modiﬁcations. When
searching for phosphopeptides, Phospho (ST) and Phospho (Y)
were also set as variable modiﬁcations. The appropriate SILAC
labels were selected and the maximum labeled amino acids
was set to 3.
For identiﬁcation of phosphorylation sites, all experiments
(phosphotyrosine IP and Myc-Dok1 IP) were ﬁltered to have a
peptide false-discovery rate (FDR) below 1%. The Myc-Dok1
IP experiments were further required to have a protein FDR
below 1%. Within the MaxQuant output, phosphorylation sites
were considered to be localized correctly if the localization
score (PTM score) was at least 0.80 (80%). Further parameters
and settings are detailed in the Supplementary Methods.
Phosphorylation Site Localization using SLoMo. DTA ﬁles
were created from the raw data using Bioworks 3.3.1 (Thermo
Fisher Scientiﬁc Inc.). The DTA ﬁles were searched using
Mascot with the search parameters as described above. Mascot
search results were exported as a pepxml ﬁle and this ﬁle was
analyzed using the SloMo software.
35
Results and Discussion
Identiﬁcation of Src Family Kinase-Mediated Phosphoryla-
tion Events, in the Presence of FGF2. Activation of ﬁbroblast
growth factor receptors (FGFRs) by FGF2 initiates a cascade of
reversible phosphorylation events on both the receptor and on
downstream effector proteins.
6 Although the core signaling
events during FGFR signaling are well established, relatively
little has been published on the global analysis of changes in
protein levels and phosphorylation events.
13,24,25 Our aim was
to generate a data set of tyrosine phosphorylated proteins that
could be mapped to the FGF signaling pathway.
We have chosen to focus speciﬁcally on a network of proteins
that may be involved in FGFR trafﬁcking and endocytosis: the
Src-mediated network. Src family kinases (SFKs) have long been
implicated in signaling by a variety of receptor tyrosine kinases
(RTKs), including FGFR, epidermal growth factor receptor
(EGFR), insulin-like growth factor-1 receptor (IGF-1R), and
hepatocyte growth factor (HGFR).
34 In FGFR signaling, upon
activation of receptor by FGF2, Src is recruited via the adaptor
protein, FRS2 and also becomes activated.
14,35 Active Src then
plays a role in regulation of the activation and transport of
FGFR from and to the plasma membrane via the Src-regulated
endosomal-actin pathway.
14,36 Considering the role of Src in
trafﬁcking of FGFRs, we decided to further characterize SFK-
mediated phosphorylation events that may be downstream of
FGFR, using a SILAC quantitative phosphoproteomics approach
coupled with chemical inhibition of SFK activity.
Prior to FGF2 stimulation, cells were treated with sodium
pervanadate to inhibit tyrosine phosphatase activity, thereby
increasing the levels of transiently phosphorylated phospho-
tyrosine proteins.
27 As phosphorylation events are the result
of a balance between kinase and phosphatase activities, inhibi-
tion of phosphatase activity will allow a history of kinase-
mediated phosphorylation events to remain during the course
of the experiment. Activation of FGFR, as measured by phos-
phorylation on residues 653 and 654, is rapid in response to
FGF2 and peaks between 3 and 10 min (Figure 1). Phospho-
rylation of well-characterized downstream target proteins of
FGFR, such as FRS2, Src, AKT and ERK peaks between 10 and
30 min. We chose to stimulate NIH 3T3 cells with FGF2 for 30
min, in the presence or absence of the selective Src family
kinase inhibitor, SU6656,
37 in order to investigate phosphory-
lation events downstream of FGFR-dependent phosphorylation
of SFKs. This was followed by quantitative analysis of the SFK-
dependent phosphorylation events. Without overexpressing
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proteome of FGF signaling,
24,25 and in the absence of pervana-
date treatment, levels of phosphopeptides remained too low
for mass spectrometric detection (data not shown).
We performed four independent experiments, three utilizing
both heavy arginine and lysine SILAC labels and one utilizing
only heavy lysine. From these experiments we identiﬁed 711
(redundant) peptides, including 430 (redundant) phosphoty-
rosine peptides (Supplementary Table S1, Supporting Informa-
tion). Representative mass spectra for two of the identiﬁed
phosphopeptides are shown in Figure 2 (see Supporting
Information for additional spectra). Given the complexity of
the starting sample (mouse whole cell lysate) and the variability
introduced during the phosphotyrosine IP and phosphopeptide
enrichment steps, we expected considerable variation between
experiments. The overlap between the four experiments is
shown in Figure S1 (Supporting Information): 50% of the
phosphotyrosine peptides were identiﬁed in 2 or more experi-
ments, while 30% were identiﬁed in 3 or more experiments. A
total of 131 unique tyrosine phosphorylation sites were identi-
ﬁed from 63 distinct proteins. Of the total 131 phosphotyrosine
sites, 6 (5%) are novel, unpublished sites according to the
PhosphoSitePlus database at www.phosphosite.org.
38
Of the peptides identiﬁed, a total of 506 were assigned a
SILAC ratio in MaxQuant, the remainder were not, due to
peptide levels being undetectable in one of the cell populations
or due to the peptide not containing a lysine (singly labeled
experiment). The three experiments utilizing both arginine and
lysine SILAC labels gave a total of 433 phosphopeptide iden-
tiﬁcations, of which 303 were tyrosine phosphorylated and were
assigned a SILAC ratio (Supplementary Table S2, Supporting
Information). The overlap between these three experiments for
the 303 phosphotyrosine peptides (139 nonredundant phos-
photyrosine peptides) is shown in Figure S2 (Supporting
Information): again, 50% of the phosphotyrosine peptides were
identiﬁed in two or more experiments and 25% were identiﬁed
in all three experiments.
A total of 80 tyrosine phosphorylation sites show a signiﬁcant
(p < 0.05) increase or decrease in abundance in the phospho-
tyrosine immunoprecipitates due to the presence of the SFK
inhibitor (Table 1). Several of the SFK-dependent tyrosine
phosphorylation sites identiﬁed are on proteins known to be
regulated by Src, including BAIP2, ZO1, paxillin, caveolin, Dok1,
EGFR, Eps8, STAM2, cortactin, FAK1, PDGFRR, p130Cas, p120
catenin, tensin, PLCγ, and SHIP2.
28,39-41 This validates the
strength of our approach for identifying Src-targets. For many
of these proteins, the speciﬁc site(s) of tyrosine phosphorylation
have not been previously identiﬁed as SFK phosphorylation
sites according to the Human Protein Reference Database.
42
Furthermore, our data agrees with previous phosphoproteomic
studies that have examined the phosphotyrosine peptide proﬁle
in 3T3 mouse ﬁbroblasts expressing a constitutively active Src
mutant, SrcY529F
26,29 in that we identify several Src-dependent
phosphotyrosine sites that were also frequently identiﬁed in
these Src-transformed cells. These include: p120 catenin pY96,
pY221, pY228, pY257, pY280; p130cas pY132; Dok1 pY295;
cortactin pY215, and ZO1 pY1164, pY1177.
Abi1, CDV3, afadin, and LPP have been identiﬁed as possible
Src substrates in a previous phosphoproteomic study using
SILAC to compare tyrosine phosphorylated proteins in SW60-
Src with those in SW60 cells.
28 Our data provides further
evidence that these proteins are Src substrates and also maps
the speciﬁc phosphorylation sites on these proteins that are
regulated by Src.
In addition, a large percentage (>30%) of the Src-dependent
phosphotyrosine sites were found in proteins not previously
reported to be regulated by Src. These include the proteins
ABLM1, CASL, Cadherin-11, Drebrin-like protein, Emerin,
PARD3, PEAR1, RMB3, and TERA.
We have not used overexpression of FGFR in these studies;
therefore, we do not expect complete overlap with previous
phospho-proteomic studies of FGF signaling that have relied
on overexpressed FGFR.
24,25 Ten FGFR1-associated tyrosine
phosphorylated proteins were identiﬁed in these overexpres-
sion studies of which four were identiﬁed here as SFK-
substrates (cortactin, p130Cas, PLCγ and paxillin). Tyrosine
phosphorylation of these proteins, therefore, appears to be both
downstream of FGFR and SFK activation. An additional 20
proteins were shown to be enriched in a phosphotyrosine IP
as a consequence of FGF-stimulation, however, tyrosine phos-
phorylation sites were not identiﬁed.
24 Of these additional
proteins, we identify both FAK1 and SHIP2 as SFK-substrates,
and also RSK2.
Src Family Kinase-Dependent Dok1 Phosphorylation
Sites. Although the global SFK-dependent phosphorylation data
set provides evidence for SFK-mediated tyrosine phosphory-
lation on a large number of proteins, it provides limited
mapping of phosphorylation sites on individual proteins. This
is not unexpected, given the limited dynamic range of pro-
teomic experiments and can be addressed through targeted
analysis of particular proteins, enabling identiﬁcation of lower
stoichiometry sites of phosphorylation. We apply this further
step to localize additional sites of phosphorylation on the
protein Dok1. We note, however, that this step in our approach
can be used to further characterize any of the proteins showing
SFK-dependency that we have identiﬁed in our global analysis.
We chose to study Dok1 based on its reported interaction
and regulation by Src
43-46 and also its role in tyrosine kinase
receptor mediated signaling.
45,47,48 Dok1 is an adaptor protein
involved in protein complex formation during cell signaling and
is a substrate for many protein tyrosine kinases. Dok1 is known
to be phosphorylated by activated Src
43,45,46 and also by
activated EGF receptor
45 and insulin receptor.
47,48 Upon ty-
rosine phosphorylation, Dok1 recruits a variety of SH2-contain-
Figure 1. Proﬁles of phosphorylation events in the presence of
FGF2. NIH 3T3s were stimulated with 20 ng/mL FGF2 for varying
lengths of time. Western blot analysis was carried out on whole
cell lysates using antibodies against indicated proteins and
phospho-proteins.
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mediation of FGF signaling.
To map phosphorylation sites of Dok1 and determine which
of these phosphorylation events are SFK-dependent, we carried
out a SILAC experiment in which Myc-Dok1 was overexpressed
and immunoprecipitated in 293T cells. Heavy and light popula-
tions were stimulated with sodium pervanadate and FGF2 (
SU6656, as described above. Phosphopeptide enrichment was
carried out on the immunoprecipitated Dok1.
The potential for distinct phosphorylation sites with distinct
patterns of regulation on the same tryptic peptide is an
important factor to take into account when analyzing data such
as these.
49 Initial examination of the MaxQuant output revealed
several identical peptides with a number of possible phospho-
rylation sites. In one particular case, the peptide, LPSPPG-
PQELLDSPPALYAEPLDSLR was separately identiﬁed as being
phosphorylated on the ﬁrst serine, the second serine, or the
tyrosine residue. The SILAC ratios were highly variable between
peptides where the phospho-group had been allocated the
same localization, and after averaging ratios for each modiﬁca-
tion the data suggested that the SILAC ratios were all un-
changed in the presence of SU6656. These data prompted us
to use the SLoMo software
33 to reanalyze the site-localization
on these enriched Dok1 phosphopeptides. Analysis of the
SLoMo output reveals that the three phosphopeptides are
indeed present and are partially coeluting. Further manual
inspection of the spectra reveals that only the phosphotyrosine
version is differentially regulated in the presence of SU6656
(Figure 3).
A total of 12 distinct sites of phosphorylation (4 serines,
and 8 tyrosines) on Dok1 were identiﬁed. According to the
PhosphositePlus database,
38 all but one has been published
Figure 2. Representative mass spectra for identiﬁcation and site localization of tyrosine phosphorylation. (a) Afadin is phosphorylated
at pY203. (b) Catenin delta-1 is phosphorylated at pY865. Peptides are labeled with 13C(6),15N(4) Arg and 13C(6) Lys. pY indicates
phosphotyrosine.
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a
protein phosphopeptide phosphosite(s) SILAC ratio % variability
ABI1 Abelson interactor 1 NTPpYKTLEPVKPPTVPNDpYMTSPAR pY197, pY212 0.083 56.942
TLEPVKPPTVPNDpYMTSPAR pY212 0.561 79.405
ABLM1 Actin-binding LIM protein 1 STSQGSINSPVpYSR pY505 0.195
AFAD Afadin LAAEVpYKDMPETSFTR pY203 0.259 85.353
EpYFTFPASK pY1230 0.482 41.237
SQEELREEKVpYQLER pY1285 0.202 43.666
AHNAK Ahnak protein VKGEpYDVTMPK pY963 0.316
BAIP2 Insulin receptor substrate p53 LSDSpYSNTLPVRK pY338 0.164
BCAR1 p130cas TQQGLpYQAPGPNPQFQSPPAK pY132 0.221
GLLSSSHHSVpYDVPPSVSK pY310 0.577 22.478
RPGPGTLpYDVPR pY391 0.326 23.664
CASL CRK-associated substrate-related protein LpYQVPNSQAASR pY91 0.352 38.486
CAV1 Caveolin-1 YVDSEGHLpYTVPIR pY14 0.378 3.108
CDH11 Cadherin-11 KDIKPEpYQYMPR pY700 0.265 13.550
CDV3 Protein CDV3 KTPQGPPEIpYSDTQFPSLQSTAK pY213 0.143 33.332
LQLDNQpYAVLENQK pY267 0.162
CTND1 Catenin delta-1 LNGPQDHNHLLpYSTIPR pY96 0.530 32.209
TVQPVPMGPDGLPVDASAVSNNpYIQTLGR pY174 0.382 17.762
NFHYPPDGYGRHYEDGpYPGGSDNpYGSLSR pY221, pY228 0.173 23.705
HYEDGYPGGSDNpYGSLSR pY228 3.003 21.770
YRPSMEGpYR pY248 0.155 44.702
QDVpYGPQPQVR pY257 0.254 30.310
FHPEPpYGLEDDQR pY280 0.289 60.708
SQSSHSpYDDSTLPLIDR pY865 0.116 45.682
SLDNNpYSTLNERGDHNR pY904 0.429 35.851
DBNL Actin-binding protein 1 ESTSFQDVGPQAPVGSVpYQK pY162 0.092 18.622
QLTQPETSpYGREPTAPVSR pY305 0.044 53.280
DOK1 Docking protein 1 TVPPPVPQDPLGSPPALpYAEPLDSLR pY295 0.579 19.218
E41L3 Band 4.1-like protein 3 SLDGEVGTGQpYATTK pY453 0.353
EGFR Epidermal growth factor receptor LLGAEEKEpYHAEGGKVPIK pY871 0.203 40.247
RPAGSVQNPVpYHNQPLHPAPGR pY1110 0.385 39.984
GPTAENAEpYLR pY1197 0.555 44.154
EMD Emerin TpYGEPESVGMSK pY106 0.074 25.481
LIYGQDSApYQSIAHYRPISNVSR pY161 0.089 33.376
LIYGQDSAYQSIAHpYRPISNVSR pY167 0.054
EPS8 Epidermal growth factor receptor kinase STPNHQVDRNpYDAVK pY524 0.504
FAK1 Focal adhesion kinase 1 AAApYLDPNLNHTPSSSTK pY4 0.174 21.969
YMEDSTpYpYKASK pY614, pY615 0.343 15.339
IFITM3 Interferon-induced transmembrane protein 3 MNHTSQAFITAASGGQPPNpYER pY20 0.576 18.836
IKEEpYEVAEMGAPHGSASVR pY27 0.433 26.578
KIRR1 Kin of IRRE-like protein 1 AVLpYADYRAPGPTR pY654 2.348
AVLYADpYRAPGPTR pY657 0.350
AVLpYADpYRAPGPTR pY654, pY657 0.432 19.452
TPpYEApYDPIGK pY753, pY756 0.467
TPYEApYDPIGK pY756 1.771 20.387
FSYTSQHSDpYGQRFQQR pY777 0.484
LPP Lipoma-preferred partner homologue SAQPSPHpYMAGPSSGQIpYGPGPR pY235, pY245 0.032 173.794
SAQPSPHYMAGPSSGQIpYGPGPR pY245 0.063 111.089
YpYEPYYAAGPSYGGR pY297 0.266
YYEPYpYAAGPSYGGR pY302 0.269 10.928
SEGDTApYGQQVQPNTWK pY318 0.137 96.380
EAApYAPPASGNQNHPGMYPVSGPK pY333 0.071 65.503
PARD3 Partitioning-defective 3 homologue ESVSTSSDQPSpYSLER pY969 0.118
ERDpYAEIQDFHR pY1076 0.514 16.397
PAXI Paxillin YAHQQPPSPLPVpYSSSAK pY88 0.395 31.523
AGEEEHVpYSFPNK pY118 0.501 24.616
PCDHGC3 Protocadherin gamma C3 APVSSLpYR pY735 0.528
PEAR1 Platelet endothelial aggregation receptor 1 ESGpYVEMKGPPSVSPPR pY41 0.138
PGFRA Platelet-derived growth factor receptor alpha QADTTQpYVPMLER pY742 0.443 32.533
SLpYDRPASYK pY762 0.410 32.001
LSADSGpYIIPLPDIDPVPEEEDLGKR pY1018 0.162 38.489
PKP4 Plakophilin-4 LQHQQLpYpYQDDSTRK pY1114, pY1115 0.387 5.041
PLCG1 PLCγ pYQQPFEDFR pY1253 0.518 5.699
Q3UGC2 Cortactin, isoform CRA_e HESQQDpYAKGFGGK pY302 0.291 17.822
RBM3 RNA-binding motif protein 3 YDSRPGGYGpYGYGR pY124 0.204
YSGGNYRDNpYDN pY151 0.318 44.561
SCAM3 Scamp3 NpYGSYSTQASAAAATAELLK pY85 0.333 30.094
SHIP2 Phosphatidylinositol-3,4,5-trisphosphate
5-phosphatase 2
TLSEVDpYAPGPGR pY1136 0.560 31.372
STAM2 Signal transducing adapter molecule 2 LVNEAPVpYSVYSK pY371 0.113 27.025
SRC8 Cortactin HASQKDpYSSGFGGK pY154 0.201
NASTFEEVVQVPSApYQK pY334 0.085 32.432
TBCB Tubulin folding cofactor B LGEpYEDVSKVEK pY98 0.172
TENC1 Tensin-2 GPLDGSPpYAQVQR pY483 0.245 38.913
LALPTAALpYGLR pY705 0.204
TENS1 Tensin-1 HAApYGGYSTPEDR pY1477 0.293
TERA Transitional endoplasmic reticulum ATPase GFGSFRFPSGNQGGAGPSQGSGGGT
GGSVYTEDNDDDLpYG
pY805 0.111
ZDHC8 Probable palmitoyltransferase ZDHHC8 KVSGVGGTTpYEISV pY711 0.432
ZO1 Tight junction protein ZO-1 YRPEAQPpYSSTGPK pY1177 0.038 62.278
SpYEQVPPPGFTSK pY1198 0.208 58.171
HEEQPAPApYEVHNR pY1164 0.112 50.945
a Variability (%) was calculated using the standard deviation of the natural logarithms of the SILAC ratios, multiplied by 100.
research articles Cunningham et al.
2322 Journal of Proteome Research • Vol. 9, No. 5, 2010previously, the exception being Ser48. Out of the 12 identiﬁed
phosphosites, 9 (Ser48, Tyr 296, Tyr337, Tyr341, Tyr362,
Tyr377, Tyr398, Tyr409, Tyr449) had a signiﬁcantly reduced
SILAC ratio (p < 0.05; Table 2), indicating that these particular
phosphorylation sites within Dok1 are regulated via Src
family kinases.
Although many sites of phosphorylation have been previ-
ously identiﬁed on Dok1, only three tyrosine residues (Y296,
Y362, and Y449) have been reported to be direct sites of Src-
mediated phosphorylation, with residue 362 described as a
binding site for Src.
46,50 We have identiﬁed these 3 tyrosine
phosphorylation sites, together with a further 5 tyrosine
residues whose phosphorylation is decreased in the presence
of SU6656. In addition, the novel phosphoserine 48 residue that
we have identiﬁed also shows SFK-dependency. Both Src-
dependent phosphorylation sites of Dok1, and sites not previ-
ously identiﬁed as Src-dependent phosphorylation sites, have
been implicated in recruitment of proteins. Phosphorylation
Figure 3. Partial co-elution of isobaric phosphopeptides. The Dok1 peptide LPSPPGPQELLDSPPALYAEPLDSLR is present in three different
singly phosphorylated forms, with phosphorylation occurring at Ser281, Ser291, and Tyr296. The selected-ion chromatogram for the
[M + 3H]3+ light precursor is shown. Comparison of the heavy/light ratios for the three versions indicates that only Tyr296 is Src-
dependent.












Peptides with reduced SILAC ratios
in the presence of SU6656
Ser48 LEFFDHKGSpSSGGGR 25.6 2 0.377 3.308
Tyr296 LPSPPGPQELLDSPPALpYAEPLDSLR 75 3 0.136 108.796
Tyr337 KKPLpYWDLYEHAQQQLLK 62.1 2 0.033 38.622
Tyr341 KKPLYWDLpYEHAQQQLLKKPLYWDLpYEHAQQQLLK 100.4 10 0.018 76.261
Tyr362 EDPIpYDEPEGLAPVPPQGLYDLPRLTDPKEDPIpYDEPEGLAPVPPQGLYDLPR 142.5 9 0.198 16.081
Tyr377 EDPIYDEPEGLAPVPPQGLpYDLPRLTDPKEDPIYDEPEGLAPVPPQGLpYDLPR 185.5 5 0.099 142.837
Tyr398 VKEEGpYELPYNPATDDYAVPPPR 30.6 1 0.084
Tyr409 EEGYELPYNPATDDpYAVPPPRVKEEGYELPYNPATDDpYAVPPPR 79.6 20 0.142 43.88
Tyr449 SHNSALpYSQVQK 72.1 21 0.167 118.322
Tyr337;Tyr341 KPLpYWDLpYEHAQQQLLK One possibility 1 0.071
Tyr362;Tyr377 LTDPKEDPIpYDEPEGLAPVPPQGLpYDLPR 18.6 4 0.030 60.981
Tyr398;Tyr409 VKEEGpYELPYNPATDDpYAVPPPR 34.1 3 0.024 23.142
Peptides with unchanged SILAC ratios in the
presence of SU6656
Ser269 ADpSHEGEVAEGKAGQGHDVLRADpSHEGEVAEGK One possibility 11 0.880 15.969
Ser281 LPpSPPGPQELLDSPPALYAEPLDSLR 39.7 5 0.772 30.703
Ser291 LPSPPGPQELLDpSPPALYAEPLDSLR 84.2 8 0.899 33.448
a SLoMo score )- 10 × (log(p). A score of 19 corresponds to a localization conﬁdence with p ) 0.0126.
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48 and phospho-
rylation of Tyr296, Tyr315, Tyr362, Tyr398, and Tyr409, has been
implicated in binding to Ras-GAP.
48,51,52
Src Family Kinase-Dependent Dok1 Binding Partners.
Using this targeted, quantitative SILAC method, not only have
we identiﬁed SFK-dependent Dok1 phosphorylation sites, but,
using the same IP sample we can also identify the SFK-
dependency of Dok1 interactions with binding partners. In
order to identify speciﬁc binding partners of Dok1 and to
determine which proteins are present as a consequence of
nonspeciﬁc interactions, we carried out a parallel SILAC
experiment comparing untransfected cells with cells in which
Myc-Dok1 was overexpressed. All cells were treated with
sodium pervanadate and FGF2 as described above.
A total of 329 proteins were identiﬁed from the IP in which
Myc-Dok1 transfected cells were compared to untransfected
cells (Supplementary Table S3, Supporting Information). The
false-discovery rate was controlled at below 1%. MaxQuant
calculated SILAC ratios for 185 of these proteins. Proteins with
SILAC ratios signiﬁcantly different from the median, as calcu-
lated using MaxQuant (p < 0.05), were considered as enriched
proteins in either cell population. Those proteins present
equally in the transfected and untransfected samples or
enriched in the untransfected cell population were considered
as contaminants in further IP experiments. Table 3 shows the
25 proteins that were enriched in the 293T cells transfected
with Dok1. Csk and NCK2, proteins known to interact with
Dok1,
53,54 showed a signiﬁcantly increased abundance in the
293T-Dok1 cells, as measured by their SILAC ratio. In addition,
Grb2, RasGAP, and PLCγ1, all known Dok1 binding partners,
44
were enriched in the 293T-Dok1 cell population, as measured
by the peak intensity. Calculation of SILAC ratios was not
possible as no peptides from these proteins were identiﬁed in
the untransfected cell population.
Of the identiﬁed proteins enriched in the 293T-Dok1 cells
∼40% are nuclear proteins that are involved in events such as
transcription, splicing, DNA replication and nucleic acid me-
tabolism. Although Dok1 is predominantly a cytoplasmic/
membrane protein, it has also been shown that a proportion
of it is found in the nucleus.
50 The function of Dok1 in the
nucleus has not yet been determined, but it may be that these
nuclear proteins are linked to its nuclear function. Alternatively,
these nuclear proteins may be binding nonspeciﬁcally to
overexpressed Dok1.
Dok1 is known to function as an adaptor protein in insulin
signaling and has recently been shown to have a role in energy
metabolism, mediating adipocyte hypertrophy and obesity
through modulation of peroxisome proliferator-activated re-
ceptor- γ (PPAR-γ) phosphorylation.
55 PPAR-γ is a nuclear
receptor that mediates the metabolism of fatty acids and
induces genes related to fatty acid metabolism. Antagonising
PPAR-γ has been shown to result in a decrease in peroxire-
doxin.
56 Interestingly, we identiﬁed enriched fatty acid synthase
(FAS), peroxiredoxin-1 (PRDX-1) and peroxiredoxin-2 (PRDX-
2) as putative Dok1 interactors. It is tempting to speculate that
these proteins may link Dok1 to PPAR- γ and their role in
energy metabolism.
The Dok1 SILAC experiment in the presence and absence
of SU6656, allowed us to identify Dok1 binding partners whose
interaction with Dok1 was regulated by SFKs. A total of 341
proteins were identiﬁed (<1% FDR) (Supplementary Table S4,
Supporting Information). The Dok1 protein itself had a SILAC
ratio of 1.05 (heavy/light, where heavy was SU6656-treated).
Of the known binding partners of Dok1, PLCγ1 and NCK2 were
signiﬁcantly enriched in the SU6656-treated cells, with SILAC
ratios of 2.04 and 2.30, respectively (Table 4). The enrichment
of PLCγ1 and NCK2 in the SU6656 treated cells indicates that
the inhibition of SFK activity, and thus phosphorylation events
mediated by SFKs, has caused an increase in the amount of
these proteins bound to Dok1. RasGAP and Csk were not
signiﬁcantly enriched in either cell population (with SILAC
ratios of 0.82 and 1.24, respectively), suggesting that these
interactions are not SFK-dependent.
For each signiﬁcant protein hit, their presence in the myc-
Dok1 vs untransfected SILAC experiment was checked in order
to see whether they may be a contaminant. Where a protein
was not signiﬁcantly enriched in the myc-Dok1 vs untrans-
fected IP (Table 3), the protein was considered a contaminant
Table 3. Proteins with Increased SILAC Ratios Due to Enrichment in Myc-Dok1 Transfected Cells




coverage (%) ratio H/L
ratio H/L
signiﬁcance
IPI00306531 NCK2 6 9.5 2.626 4.27 × 102
IPI00449049 Poly [ADP-ribose] polymerase 1 (PARP1) 2 2.4 2.750 3.57 × 102
IPI00887678 Peptidyl-prolyl cis-trans isomerase A 6 27.4 2.762 3.51 × 102
IPI00007188 ADP/ATP translocase 2 11 25.8 3.070 2.27 × 102
IPI00293655 ATP-dependent RNA helicase DDX1 5 6.4 3.363 1.52 × 102
IPI00396435 Putative pre-mRNA-splicing factor
ATP-dependent RNA helicase DHX15
2 1.5 3.391 1.47 × 102
IPI00296337 DNA-dependent protein kinase catalytic subunit 4 1.2 3.572 1.15 × 102
IPI00410693 Plasminogen activator inhibitor 1
RNA-binding protein
3 6.6 3.609 1.10 × 102
IPI00215790 60S ribosomal protein L38 4 47.1 3.842 8.11 × 103
IPI00386604 Putative uncharacterized protein 6 15 4.603 3.18 × 103
IPI00026781 Fatty acid synthase 7 3.3 5.025 1.95 × 103
IPI00018350 DNA replication licensing factor MCM5 6 10.6 5.671 9.55 × 104
IPI00376798 60S ribosomal protein L11 9 40.4 6.067 6.29 × 104
IPI00024067 Clathrin heavy chain 1 3 2.5 6.126 5.92 × 104
IPI00396485 Elongation factor 1-alpha 1 12 16 6.882 2.78 × 104
IPI00016610 Poly(rC)-binding protein 1 2 6.7 8.265 7.81 × 105
IPI00013214 DNA replication licensing factor MCM3 9 10.7 12.162 3.81 × 105
IPI00156005 RNA-binding protein Nova-2 1 2.2 19.196 5.92 × 108
IPI00013212 Tyrosine-protein kinase CSK 14 29.6 19.795 4.37 × 108
IPI00186290 Elongation factor 2 11 11.9 28.888 8.16 × 1010
IPI00000874 Peroxiredoxin-1 8 43.2 30.256 4.86 × 1010
IPI00216746 Heterogeneous nuclear ribonucleoprotein K 4 13.6 30.681 4.15 × 1010
IPI00027350 Peroxiredoxin-2 4 27.8 31.323 3.28 × 1010
IPI00011200 D-3-phosphoglycerate dehydrogenase 13 25.5 77.030 3.25 × 1015
IPI00015287 Docking protein 1 (Dok1) 53 80.5 82.827 1.15 × 1015
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the remaining 14 proteins that were signiﬁcantly enriched in
the SU6656 treated cells and the 4 proteins that were enriched
in the non-SU6656 treated cells. A number of proteins are
absent in the myc-Dok1 vs untransfected SILAC experiment
(Table 4). In these cases, the possibility remains that the protein
may not be a true Dok1 interacting partner, an important
consideration when selecting proteins for further biological
analysis.
The shuttling of Dok1 between the nucleus and cytoplasm
has been shown to be dependent on Src-mediated tyrosine
phosphorylation.
50 Phosphorylation of Dok1 by Src causes
accumulation of Dok1 in the cytoplasm, assumed to be caused
by an inhibition of nuclear import.
50 Interestingly, our data
shows that, in the presence of the SFK inhibitor, SU6656, Dok1
bound to more nuclear proteins than in the absence of SU6656.
The inhibition of nuclear import due to Src-phosphorylation
is presumably due to a lack of interaction with nuclear import
transporters. Our data shows an increased amount of Dok1-
bound transportin-1, a nuclear import protein, in the absence
of Src-induced phosphorylation, consistent with Src-dependent
inhibition of nuclear import. However, we note that transpor-
tin-1 was not identiﬁed as a Dok1-binding protein in the
previous experiment; therefore, we cannot be certain that this
is a true Dok1 interactor.
IRS4 and SHIP2 were also found enriched in SU6656 treated
cells, suggesting that they may bind to Dok1 directly or
indirectly in a SFK-dependent manner. Dok1 has not previously
been linked to either protein, although all three proteins play
a role in insulin signaling
47,48,57,58 and both IRS4 and SHIP2
play a role in FGF/FGFR signaling.
24 Although a direct link
between Dok1 and IRS4 has not been previously reported, IRS4
is known to interact with CRKL, which is also a known binding
partner of Dok1.
59 The quantitative proteomics approach
described here has not only identiﬁed additional putative,
binding partners of Dok1 but has also provided information
about the regulation of these interactions by SFKs. Future
studies will be needed to investigate the role of the novel SFK-
dependent phosphorylation sites in these interactions.
Conclusions
We have implemented a differential phosphoproteomics
approach for dissection of the SFK-mediated interaction net-
work within the FGF signaling pathway. We have focused on
those phosphorylation sites which are dependent on activation
of SFK activity and then on Dok1, with the identiﬁcation of
both SFK-dependent and independent sites of phosphorylation,
and SFK-dependent Dok1 binding partners. The study has
revealed the phosphorylation of multiple downstream kinases
and adaptor/scaffolding proteins and has identiﬁed a signiﬁ-
cant number of proteins potentially involved in FGF signaling
for further functional scrutiny. We note that the ﬁnal protein-
targeted step in our approach can be used to further character-
ize any of the proteins showing SFK-dependency that we have
identiﬁed in our global analysis. Indeed, data from such
experiments could be combined to provide a detailed tyrosine
phosphorylation map of events occurring within the Src-
mediated node of FGFR signaling. The experimental approach
employed in this study is readily applicable to deeper analysis
of both the FGF and other receptor tyrosine kinases.
Supplementary Methods
Peptide and Protein Identiﬁcation and Quantitation.
Antiphosphotyrosine IP (SILAC). Fifteen raw ﬁles were ana-
lyzed by MaxQuant, 4 were following phosphopeptide enrich-
ment (and therefore searched allowing phosphorylation as a
variable modiﬁcation). Eleven were either ﬂow-throughs from
enrichments or unenriched controls (therefore searched with-
out allowing phosphorylation). Three experiments (13 raw ﬁles)
employed Lys6, Arg10 labels, while one experiment employed
only Lys6 label (2 raw ﬁles). All 15 ﬁles were combined in the
‘Identify’ step. An experimental design template was used to
mark raw ﬁles as being from experiment 1, 2, 3, or 4 and also
to indicate that the labeling in experiment 3 was inverted.
Identiﬁcations were ﬁltered using a peptide FDR of 0.01 and a
protein FDR of 1.00 (no ﬁltering at the protein level). Supple-
mentary Table S1 (Supporting Information) was created from
the evidence.txt output for all four experiments, by sorting
according to phospho (Y) site ID. Supplementary Table S2
Table 4. Proteins Identiﬁed in a Myc-Dok1 Immunoprecipitation whose SILAC Ratios are Signiﬁcantly Changed Due to the
Presence of SU6656









Proteins with reduced SILAC ratios due to presence of SU6656
IPI00873058 Paired Box 1 2 1.9 0.016 1.05 × 10-21 a
IPI00440577 IGKV2-24 protein 1 3.8 0.042 2.26 × 10-13 a
IPI00798360 SAP domain containing ribonucleoprotein 1 4.3 0.373 1.10 × 102 a
IPI00104050 Thyroid hormone receptor-associated protein 3 3 2.7 0.391 1.45 × 102 a
Proteins with increased SILAC ratios due to presence of SU6656
IPI00001159 Translational activator GCN1 5 1.4 1.753 4.37 × 102 a
IPI00003965 Ubiquitin carboxyl-terminal hydrolase 7 7 4.5 1.758 4.29 × 102 b
IPI00031647 Programmed cell death protein 2-like 2 3.4 1.797 3.69 × 102 b
IPI00024364 Transportin-1;Importin beta-2 5 3.8 1.823 3.34 × 102 a
IPI00514856 Ubiquitin-associated protein 2-like 4 1.8 1.834 3.20 × 102 b
IPI00016932 Phosphatidylinositol-3,4,5-trisphosphate
5-phosphatase 2 (SHIP2)
2 1.4 1.870 2.79 × 102 a
IPI00221012 Probable ubiquitin carboxyl-terminal hydrolase FAF-X 6 2.7 1.954 2.01 × 102 b
IPI00020729 Insulin receptor substrate 4 (IRS4) 2 2.1 1.980 1.81 × 102 a
IPI00383849 Phospholipase C, gamma 1 (PLCγ) 8 4.3 2.036 1.46 × 102 b
IPI00029705 Gamma-tubulin complex component 2 1 1.2 2.125 1.03 × 102 a
IPI00306531 NCK adaptor protein 2 1 4.5 2.302 5.11 × 103 2.6
IPI00217223 Multifunctional protein ADE2 3 5.8 2.366 3.97 × 103 b
IPI00410590 LSM14 protein homologue A 2 2.2 2.447 2.89 × 103 a
IPI00011631 Centromere/kinetochore protein zw10 homologue 2 3.7 3.163 1.79 × 104 a
a Not detected.
b Detected only in Dok1 immunoprecipitation and not in untransfected control; therefore, no ratio could be calculated.
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output for all dual labeled experiments, by sorting according
to phospho (Y) site ID and SILAC ratio. Reverse hits and
contaminants are not shown. All ratios obtained from Max-
Quant were adjusted using a correction factor to allow for
mixing error. This correction factor was calculated by com-
bining all unenriched pre-IP control samples and normalizing
peptide ratios so that the median of their logarithms is zero.
In order to calculate the probability cut-offs (p ) 0.05), the
value for 2 × the standard deviation of the control ratio
logarithms was calculated. Ratios were deemed signiﬁcantly
changed if they were <0.616 or >1.624. The correction factor
was then applied to the enriched samples, and the means of
the corrected ratio logarithms for each peptide were calculated.
Variability (%) was calculated using the standard deviation of
the natural logarithms of the SILAC ratios, multiplied by 100.
Myc-Dok1 IP Plus/Minus Src Drug (SILAC). Two separate
experiments were carried out, resulting in 41 raw ﬁles. These
were analyzed by MaxQuant, 3 were following phosphopeptide
enrichment (and therefore searched allowing phosphorylation
as a variable modiﬁcation). Thiry-six were either gel-slices with
no TiO2 enrichment or ﬂow-throughs from enrichments, and
two were pre-IP control samples (therefore searched without
allowing phosphorylation). Both experiments employed Lys6,
Arg10 labels. All 41 ﬁles were combined in the ‘Identify’ step.
To obtain the phosphorylation-speciﬁc output columns, the
phosphorylated samples were selected to be at the top of the
list of ﬁles for ‘Identify’ to process. Identiﬁcations were ﬁltered
using a peptide FDR of 0.01 and a protein FDR of 0.01. An
experimental design template was used to mark raw ﬁles as
being from experiment 1 or 2. Supplementary Table S3 (Sup-
porting Information) was created from the proteingroups.txt
output, by sorting according to normalized SILAC Ratio.
Reverse hits and contaminants are not shown. For the enriched
Dok1 gel slices, a correction factor was applied to each peptide
ratio, calculated from nonenriched pre-IP control samples as
described above. Ratios were deemed signiﬁcantly changed if
they were <0.612 or >1.635.
Myc-Dok1 IP versus Untransfected (SILAC). Two separate
experiments were carried out, resulting in 34 raw ﬁles. These
were analyzed by MaxQuant, 2 were following phosphopeptide
enrichment (and therefore searched allowing phosphorylation
as a variable modiﬁcation). Thirty-two were either gel-slices
with no TiO2 enrichment or ﬂow-throughs from enrichments
(therefore searched without allowing phosphorylation). Both
experiments employed Lys6, Arg10 labels. All 34 ﬁles were
combined in the ‘Identify’ step. In order to obtain the phos-
phorylation-speciﬁc output columns, the phosphorylated
samples were selected to be at the top of the list of ﬁles for
‘Identify’. Identiﬁcations were ﬁltered using a peptide FDR of
0.01 and a protein FDR of 0.01. An experimental design
template was used to mark raw ﬁles as being from experiment
1 or 2. Supplementary Table S4 (Supporting Information) was
created from the proteingroups.txt output, by sorting according
to normalized SILAC Ratio. Reverse hits and contaminants are
not shown.
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identiﬁed in the myc-Dok1 ( SU6656 SILAC experiment.
Supplementary Figure S1, Overlap of phosphotyrosine peptide
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